Jack CR, et al. - Via performing a longitudinal cohort study that included 480 participants without dementia (aged 60 years or older), researchers ascertained the associations between amyloid, tau, and neurodegeneration biomarker profiles and memory decline, and determined if biomarkers rendered incremental prognostic value beyond more readily available clinical and genetic information. Among older persons without baseline dementia, when followed up for a median of 4.8 years, a little but statistically meaningful improvement in the prediction of memory decline over a model with more readily available clinical and genetic variables was observed through a prediction model that included amyloid positron emission tomography (PET), tau PET, and magnetic resonance imaging cortical thickness. However, the uncertainty of the clinical importance of this difference was noted.